Thus, LONP1 inhibition provides a pharmacological tool to increase mitochondrial content in VHL-deficient ccRCC and can sensitize therapy-resistant ccRCC cells to sorafenib. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.